|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hagan S, Orr MC and Doyle B: Targeted
therapies in colorectal cancer-an integrative view by PPPM. EPMA J.
4(3)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kocarnik JM, Shiovitz S and Phipps AI:
Molecular phenotypes of colorectal cancer and potential clinical
applications. Gastroenterol Rep (Oxf). 3:269–276. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kerr DJ and Midgley R: Defective mismatch
repair in colon cancer: A prognostic or predictive biomarker? J
Clin Oncol. 28:3210–3212. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nojadeh JN, Behrouz Sharif S and Sakhinia
E: Microsatellite instability in colorectal cancer. Excli J.
17:159–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Lenz HJ, Ou FS, Venook AP, Hochster HS,
Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD,
Zemla T, et al: Impact of consensus molecular subtype on survival
in patients with metastatic colorectal cancer: Results From
CALGB/SWOG 80405 (Alliance). J Clin Oncol. 37:1876–1885.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ragulan C, Eason K, Fontana E, Nyamundanda
G, Tarazona N, Patil Y, Poudel P, Lawlor RT, Del Rio M, Koo SL, et
al: Analytical validation of multiplex biomarker assay to stratify
colorectal cancer into molecular subtypes. Sci Rep.
9(7665)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tóth C, Sükösd F, Valicsek E, Herpel E,
Schirmacher P and Tiszlavicz L: Loss of CDX2 gene expression is
associated with DNA repair proteins and is a crucial member of the
Wnt signaling pathway in liver metastasis of colorectal cancer.
Oncol Lett. 15:3586–3593. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Olsen J, Eiholm S, Kirkeby LT, Espersen
ML, Jess P, Gögenür I, Olsen J and Troelsen JT: CDX2 downregulation
is associated with poor differentiation and MMR deficiency in colon
cancer. Exp Mol Pathol. 100:59–66. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grabsch H, Dattani M, Barker L, Maughan N,
Maude K, Hansen O, Gabbert HE, Quirke P and Mueller W: Expression
of DNA double-strand break repair proteins ATM and BRCA1 predicts
survival in colorectal cancer. Clin Cancer Res. 12:1494–1500.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang GH, Zhao CM, Huang Y, Wang W, Zhang S
and Wang X: BRCA1 and BRCA2 expression patterns and prognostic
significance in digestive system cancers. Hum Pathol. 71:135–144.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Krajewska M, Fehrmann RS, de Vries EG and
van Vugt MA: Regulators of homologous recombination repair as novel
targets for cancer treatment. Front Genet. 6(96)2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Petrovic N, Davidovic R, Bajic V,
Obradovic M and Isenovic RE: MicroRNA in breast cancer: The
association with BRCA1/2. Cancer Biomark. 19:119–128.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang Y, Huang JW, Calses P, Kemp CJ and
Taniguchi T: miR-96 downregulates REV1 and RAD51 to promote
cellular sensitivity to cisplatin and PARP inhibition. Cancer Res.
72:4037–4046. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Moskwa P, Buffa FM, Pan Y, Panchakshari R,
Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K,
Weinstock DM, et al: miR-182-mediated downregulation of BRCA1
impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell.
41:210–220. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wahner Hendrickson AE, Menefee ME,
Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F,
Kayode O, Flatten KS, Harrell MI, et al: A Phase I Clinical Trial
of the Poly(ADP-ribose) polymerase inhibitor veliparib and weekly
topotecan in patients with solid tumors. Clin Cancer Res.
24:744–752. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Svensson MC, Warfvinge CF, Fristedt R,
Hedner C, Borg D, Eberhard J, Micke P, Nodin B, Leandersson K and
Jirström K: The integrative clinical impact of tumor-infiltrating T
lymphocytes and NK cells in relation to B lymphocyte and plasma
cell density in esophageal and gastric adenocarcinoma. Oncotarget.
8:72108–72126. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Byrne M and Saif MW: Selecting treatment
options in refractory metastatic colorectal cancer. Onco Targets
Ther. 12:2271–2278. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nayak SS, Roy P, Arora N, Arun I, Roy MK,
Banerjee S, Mallick I and Mallath MK: Prevalence estimation of
microsatellite instability in colorectal cancers using tissue
microarray based methods-A tertiary care center experience. Indian
J Pathol Microbiol. 61:520–525. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mazières J, Brugger W, Cappuzzo F, Middel
P, Frosch A, Bara I, Klingelschmitt G and Klughammer B: Evaluation
of EGFR protein expression by immunohistochemistry using H-score
and the magnification rule: Re-analysis of the SATURN study. Lung
Cancer. 82:231–237. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bartley AN, Hamilton SR, Alsabeh R,
Ambinder EP, Berman M, Collins E, Fitzgibbons PL, Gress DM, Nowak
JA, Samowitz WS, et al: Members of the Cancer Biomarker Reporting
Workgroup, College of American Pathologists Template for reporting
results of biomarker testing of specimens from patients with
carcinoma of the colon and rectum. Arch Pathol Lab Med. 138:166–70.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jørgensen AS, Rasmussen AM, Andersen NKM,
Andersen SK, Emborg J, Røge R and Østergaard LR: Using cell nuclei
features to detect colon cancer tissue in hematoxylin and eosin
stained slides. Cytometry A. 91:785–793. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Korlimarla A, Prabhu JS, Anupama CE,
Remacle J, Wahi K and Sridhar TS: Separate quality-control measures
are necessary for estimation of RNA and methylated DNA from
formalin-fixed, paraffin-embedded specimens by quantitative PCR. J
Mol Diagn. 16:253–260. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Korlimarla A, Prabhu JS, Remacle J,
Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa
M, et al: Identification of BRCA1 deficiency using multi-analyte
estimation of BRCA1 and its repressors in FFPE tumor samples from
patients with triple negative breast cancer. PLoS One.
11(e0153113)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ryan E, Sheahan K, Creavin B, Mohan HM and
Winter DC: The current value of determining the mismatch repair
status of colorectal cancer: A rationale for routine testing. Crit
Rev Oncol Hematol. 116:38–57. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology.
138:2073–2087.e3. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kumar A, Jain M, Yadav A, Kumari N and
Krishnani N: Pattern of mismatch repair protein loss and its
clinicopathological correlation in colorectal cancer in North
India. S Afr J Surg. 56:25–29. 2018.PubMed/NCBI
|
|
30
|
Chen W, Swanson BJ and Frankel WL:
Molecular genetics of microsatellite-unstable colorectal cancer for
pathologists. Diagn Pathol. 12(24)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Öhrling K, Edler D, Hallström M and
Ragnhammar P: Mismatch repair protein expression is an independent
prognostic factor in sporadic colorectal cancer. Acta Oncol.
49:797–804. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Neumann J, Heinemann V, Engel J, Kirchner
T and Stintzing S: The prognostic impact of CDX2 correlates with
the underlying mismatch repair status and BRAF mutational status
but not with distant metastasis in colorectal cancer. Virchows
Arch. 473:199–207. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Baba Y, Nosho K, Shima K, Freed E, Irahara
N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS,
et al: Relationship of CDX2 loss with molecular features and
prognosis in colorectal cancer. Clin Cancer Res. 15:4665–4673.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Naseem M, Xiu J, Salem ME, Goldberg RM,
Vanderwalde AM, Grothey A, Philip PA, Seeber A, Puccini A, Tokunaga
R, et al: Characteristics of colorectal cancer (CRC) patients with
BRCA1 and BRCA2 mutations. J Clin Oncol. 37 (Suppl 4):S606.
2019.
|
|
35
|
Feliubadaló L, López-Fernández A, Pineda
M, Díez O, Del Valle J, Gutiérrez-Enríquez S, Teulé A, González S,
Stjepanovic N, Salinas M, et al: Opportunistic testing of BRCA1,
BRCA2 and mismatch repair genes improves the yield of phenotype
driven hereditary cancer gene panels. Int J Cancer. 145:2682–2691.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ma Y, Liang AJ, Fan YP, Huang YR, Zhao XM,
Sun Y and Chen XF: Dysregulation and functional roles of
miR-183-96-182 cluster in cancer cell proliferation, invasion and
metastasis. Oncotarget. 7:42805–42825. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Dambal S, Shah M, Mihelich B and Nonn L:
The microRNA-183 cluster: The family that plays together stays
together. Nucleic Acids Res. 43:7173–7188. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Milner R, Wombwell H, Eckersley S, Barnes
D, Warwicker J, Van Dorp E, Rowlinson R, Dearden S, Hughes G,
Harbron C, et al: Validation of the BRCA1 antibody MS110 and the
utility of BRCA1 as a patient selection biomarker in
immunohistochemical analysis of breast and ovarian tumours.
Virchows Arch. 462:269–279. 2013.PubMed/NCBI View Article : Google Scholar
|
